Experts across the globe point to the harms of drug companies’ influence on research, practice, and education in healthcare noting that it compromises patient care.
Current standards for clinical trials rely on statistical methods that allow for ineffective treatments to gain approval.
A new special issue brings together articles exploring the harmful effects of simultaneous multiple medication use.
A closer look at a new study reporting that the supplement D-cycloserine improved anxiety when used with exposure therapy.
A new study reports that the supplement EPA improved ADHD symptoms but a closer look calls these results into question.
When it comes to ADHD, some researchers suggest that medical textbooks provide inaccurate and misleading information.
A new update to the NICE guideline for depression suggests providers discuss long-term, severe antidepressant withdrawal symptoms.
A new article documents the “flimsy evidence” behind the recent FDA approval of the party drug esketamine for the treatment of depression.
A new review, published in BMJ Evidence-Based Medicine, concludes that antidepressants should not be used as the risks outweigh evidence for benefits.
Despite their finding, the researchers suggest that SSRIs be given to people who do not meet criteria for depression or anxiety.
Researchers critique the German S3 guidelines for depression promoting antidepressants.
: A new review finds evidence of spin and the misrepresentation of clinical trials with non-significant results.
The approval of the digital antipsychotic may open the door for more pharmaceutical company profits without evidence of benefits to patients.
An analysis of last year’s positive finding in The Lancet about antidepressant efficacy shows errors, obfuscations, and misrepresentations.
MIA's Gavin Crowell-Williamson interviews PharmedOut founder Dr. Adriane Fugh-Berman about Big Pharma's influence on medical education.
MIA's Peter Simons interviews David Cohen, PhD, on his path to researching mental health, coercive practices, and discontinuation from psychiatric drugs.
Research illustrates privacy concerns with how mental health applications collect and share users’ data.
Akansha Vaswani interviews Dr. John Read about the influences on his work and his research on madness, psychosis, and the mental health industry.
Researchers compare differences between research and clinical diagnoses of ADHD and explore the consistency of clinical determinations over time
Industry-funded continuing medical education (CME) influences physicians to prescribe more opioids, focus less on the consequences.
A new study casts doubt on whether such biotypes for depression exist.
New study finds that antidepressants may negatively impact recovery after psychiatric hospitalization.
Could the statistical phenomenon of regression to the mean be responsible for the dramatic effects of placebo—as well as the supposed effectiveness of some psychiatric drugs?
Researchers examine how rapid discontinuation can mimic the relapse of mental health symptoms and confound psychiatric drug studies.
A new study provides an insider’s look into how psychiatrists view the establishment of drug-free programs in Norway.